EGFR and non-small cell lung carcinoma: On the other hand, gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase and has been shown to suppress the activation of EGFR signaling required for cell survival and proliferation in non-small-cell lung-cancer (NSCLC) cell lines.